Impact of Assessment and Management of Comorbidities in Internal Medicine on Cardiovascular Risk
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Screening and management of cormobidities.
- Who it may be relevant to
- Registry conditions: Adverse Cardiac Event, Major Adverse Cardiac Events. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Impact du Bilan et de la Prise en Charge Des comorbidités en médecine Interne Sur le Risque Cardiovasculaire
Overview
The aim of assessing and managing cardiovascular risk is to avoid, limit or delay cardiovascular morbidity and mortality. Planned internal medicine hospitalization is developed around the management of cardiovascular risk in patients at high cardiovascular risk, whether in primary prevention or secondary prevention. During planned hospitalization, patients benefit from comprehensive, personalized and adapted care for their comorbidities and their CVRF (cardiovascular risk factors). This study will make it possible to evaluate this overall course of multidisciplinary management of comorbidities of patients at high cardiovascular risk.
Detailed description
The aim of assessing and managing cardiovascular risk is to avoid, limit or delay cardiovascular morbidity and mortality. Planned internal medicine is developed around the management of cardiovascular risk in patients at high cardiovascular risk, whether in primary prevention patients, combining several cardiovascular risk factors CVRF (arterial hypertension, metabolic syndrome, diabetes, dyslipidemia, etc.), or patients in secondary prevention who have several CVRFs and have already had a major cardiovascular event such as ischemic heart disease, heart failure.
During scheduled hospitalization, patients benefit from comprehensive care. Additional examinations include measurement of blood pressure, cardiac ultrasound, vascular Dopplers, usual biological assessment (lipid, glycemic, renal, iron assessment, CRP), and on a case-by-case basis, ventilatory polygraphy to screen for obstructive sleep apnea hypopnea syndrome, pulmonary function tests if the patient is a smoker to screen for chronic obstructive pulmonary disease, coronary function test to screen for ischemic heart disease if indicated. Comorbidities are thus identified and summarized, and patients benefit from personalized and adapted care for their comorbidities and CVRFs.
Cardiovascular risk reduction strategy programs targeting high-risk patients are essential and their evaluation is necessary.This study will make it possible to evaluate this overall course of multidisciplinary management of comorbidities in patients at high cardiovascular risk in internal medicine.
The innovative nature of the project is the possibility to cross-reference the comorbidities and the cardiovascular and metabolic data of these patients at high cardiovascular risk with their evolving risk level over time. This will also make it possible to highlight which markers are the most effective to better stratify cardiovascular risk, or even consider personalized phenotyping. The coexistence of all these parameters within the same database represents a unique opportunity to study their respective influences in a population of patients at high cardiovascular risk.
Interventions
- Other Screening and management of cormobidities
During the routine care assessment and as part of the research, patients will : * Fill in cardiovascular risk assessment score: Life's simple 7 * Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection. After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior t
Primary outcome measures
- Screening and management of comorbidities effect on cardiovascular risk factors [Time frame: 3 months after enrollment]
Secondary outcome measures (11)
- Screening and management of comorbidities effect on cardiovascular risk factors [Time frame: 12 months after enrollment]
- Screening and management of comorbidities effect on blood pressure [Time frame: 3 and 12 months after enrollment]
- Screening and management of comorbidities effect on patient's weight [Time frame: 3 and 12 months after enrollment]
- Screening and management of comorbidities effect on the balance of cholesterol [Time frame: 3 and 12 months after enrollment]
- Screening and management of comorbidities effect on tobacco consumption [Time frame: 3 and 12 months after enrollment]
- Screening and management of comorbidities effect on the balance of blood sugar level [Time frame: 3 and 12 months after enrollment]
- Screening and management of comorbidities effect on A1C level [Time frame: 3 and 12 months after enrollment]
- Cardivascular events incidence [Time frame: 12 months after enrollment]
- Initial participant's comorbidities [Time frame: At enrollment]
- C-reactive protein levels [Time frame: At enrollment]
- Lipoprotein a levels [Time frame: At enrollment]
Eligibility criteria
Inclusion criteria
- High-Risk Cardiovascular patients either receiving:
- Primary prevention because they have never had a cardiovascular event but have several cardiovascular risk factors such as high blood pressure particularly resistant, metabolic syndrome, diabetes , dyslipidemia, metabolic steatosis
- Or secondary prevention because they have already had a major cardiovascular event such as ischemic heart disease, heart failure
- Aged 18 and over
- Patient benefiting from comorbidities assessment during their planned hospitalization in the internal medicine department.
Exclusion criteria
- Patient refusal
- Subject not registered in social security system
- Pregnant or breastfeeding woman
- Patient unable to give their informed consent, protected adult, vulnerable people
- Subject deprived of liberty by judicial or administrative decision
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
France · 1 center
- University Hospital — Montpellier
Identifiers
NCT: NCT06204549 · RECHMPL22_0390 · 2023-A00012-43